Targeting immune checkpoints in hematological malignancies

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology. While immunotherapeutic approaches such as stem cell transplantation and anti-cancer monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Salik, Basit, Smyth, Mark J., Nakamura, Kyohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425174/
https://www.ncbi.nlm.nih.gov/pubmed/32787882
http://dx.doi.org/10.1186/s13045-020-00947-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425174/
https://www.ncbi.nlm.nih.gov/pubmed/32787882
http://dx.doi.org/10.1186/s13045-020-00947-6

Ejemplares similares